Enzymatic Therapies' two new kava products promoted for "normal" mental well-being.
This article was originally published in The Tan Sheet
Executive Summary
ENZYMATIC THERAPIES INTRODUCING KAVA-30 kava capsules, standardized to contain 30% kavalactones, to the trade at Natural Products Expo West in Anaheim, Calif. March 11-15. The new product will be available in a 60-capsule bottle, or a 30-day supply. Kava promotes "normal" mental well-being, the company said, predicting the substance, made from the root of the Piper methysticum plant, could become as popular as St. John's wort for depression. The product will be sold in health food stores alongside other Enzymatic Therapies products, and will retail for about $17.95.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning